Fetal hydantoin syndrome

Description

Fetal hydantoin syndrome is a fetopathy likely to occur when a pregnant woman takes the anticonvulsant drug phenytoin (diphenylhydantoin) for epileptic seizures. In utero exposure to this drug may result in a characteristic dysmorphic syndrome in the newborn, including low-set hair, short neck with pterygium colli, small nose, deep nasal bridge, epicanthus, hypertelorism, large mouth, malformed ears, hypoplastic distal phalanges of the fingers and toes and finger-like thumbs. These dysmorphic features are often associated with growth retardation and delayed psychomotor development. The mechanism underlying these anomalies has been shown to depend on maternal genetic characteristics, i.e. on maternal capacity to detoxify intermediate metabolites of phenytoin.

Index terms

Fetal hydantoin syndrome
dysmorphism due to hydantoin

Exclusions from above levels

http://id.who.int/icd/entity/733825440 – Inborn errors of metabolism

Sibling codes

LD2F.00 – Fetal alcohol syndrome
LD2F.02 – Embryofetopathy due to oral anticoagulant therapy
LD2F.03 – Fetal Valproate Spectrum Disorder
LD2F.0Y – Other specified toxic or drug-related embryofetopathies
LD2F.0Z – Toxic or drug-related embryofetopathies, unspecified

Foundation entity

Fetal hydantoin syndrome – http://id.who.int/icd/entity/1894344911

Part of: LD2F.0: Toxic or drug-related embryofetopathies › LD2F: Syndromes with multiple structural anomalies, without predominant body system involvement › 20: Developmental anomalies